CTIS2022-500903-38-00RecruitingPhase 1
38RC22.210 LIVERNET1
niversity Hospital Grenoble0 sites52 target enrollmentStarted: August 25, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 52
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 1
Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1pancreatic ductal adenocarcinomaCTIS2022-500905-42-00niversity Hospital Grenoble52
Active, not recruiting
Phase 1
A Study of ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer.CTIS2023-504514-29-00Astellas Pharma Global Development Inc.240
Active, not recruiting
Phase 1
Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)Adult patients with adverse Risk Acute Myeloblastic LeukemiaCTIS2022-502585-25-00Centre Hospitalier Universitaire De Nantes12
Recruiting
Phase 1
A Randomized, double-blind, placebo-controlled, three-way cross-over study to assess the pharmacodynamic effects of an authorised and a new compound on nerve excitability threshold tracking in healthy male subjects.neuropathic painCTIS2024-510721-26-00Centre for Human Drug Research18
Recruiting
Phase 1
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sage-319 In Healthy Adult Participants.Disorders characterized by a deficit in GABAergic signaling and cerebellar circuitry.CTIS2024-512987-74-00Sage Therapeutics Inc.104